Last10K.com

Marina Biotech, Inc. (MRNA) SEC Filing 10-K Annual report for the fiscal year ending Thursday, December 31, 2015

Adhera Therapeutics, Inc.

CIK: 737207
Document and Entity Information - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2015
Mar. 30, 2016
Jun. 30, 2015
Document and Entity Information [Abstract]   
Entity Registrant NameMarina Biotech, Inc.  
Entity Central Index Key0000737207  
Trading Symbolmrna  
Entity Current Reporting StatusYes  
Entity Voluntary FilersNo  
Current Fiscal Year End Date--12-31  
Entity Filer CategorySmaller Reporting Company  
Entity Well-known Seasoned IssuerNo  
Entity Common Stock, Shares Outstanding 29,284,819 
Entity Public Float  $ 11.2
Document Type10-K  
Document Period End DateDec. 31, 2015  
Amendment Flagfalse  
Document Fiscal Year Focus2015  
Document Fiscal Period FocusFY  

View differences made from one year to another to evaluate Adhera Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Adhera Therapeutics, Inc..

Continue

Assess how Adhera Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Adhera Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2016 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (parentheticals)
Consolidated Statement Of Stockholders' Equity (deficit)
Consolidated Statement Of Stockholders' Equity (deficit) (parentheticals)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Operations
Accrued Expenses
Accrued Expenses (details)
Accrued Expenses (tables)
Business, Liquidity And Summary Of Significant Accounting Policies
Business, Liquidity And Summary Of Significant Accounting Policies (detail Textuals 1)
Business, Liquidity And Summary Of Significant Accounting Policies (detail Textuals)
Business, Liquidity And Summary Of Significant Accounting Policies (details 1)
Business, Liquidity And Summary Of Significant Accounting Policies (details 2)
Business, Liquidity And Summary Of Significant Accounting Policies (details 3)
Business, Liquidity And Summary Of Significant Accounting Policies (details)
Business, Liquidity And Summary Of Significant Accounting Policies (policies)
Business, Liquidity And Summary Of Significant Accounting Policies (tables)
Commitments And Contingencies
Income Taxes
Income Taxes (detail Textuals)
Income Taxes (details)
Income Taxes (tables)
Intangible Assets
Intangible Assets (detail Textuals 1)
Intangible Assets (detail Textuals)
Intellectual Property And Collaborative Agreements
Intellectual Property And Collaborative Agreements (detail Textuals 1)
Intellectual Property And Collaborative Agreements (detail Textuals)
Notes Payable
Notes Payable (detail Textuals)
Prepaid Expenses And Other Current Assets
Prepaid Expenses And Other Current Assets (details)
Prepaid Expenses And Other Current Assets (tables)
Restructuring Charges
Restructuring Charges (detail Textuals)
Stock Incentive Plans
Stock Incentive Plans (detail Textuals)
Stock Incentive Plans (stock Option Activity) (details 1)
Stock Incentive Plans (stock Options Outstanding ) (details 2)
Stock Incentive Plans (stock-based Compensation Expense) (details)
Stock Incentive Plans (tables)
Stockholders' Equity
Stockholders' Equity (common Stock) (details Textuals 1)
Stockholders' Equity (details)
Stockholders' Equity (preferred Stock) (detail Textuals)
Stockholders' Equity (tables)
Stockholders' Equity (warrants) (details Textuals 2)
Subsequent Events

Material Contracts, Statements, Certifications & more

Adhera Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

CIK: 737207
Form Type: 10-K Annual Report
Accession Number: 0001571049-16-013489
Submitted to the SEC: Wed Mar 30 2016 4:17:15 PM EST
Accepted by the SEC: Wed Mar 30 2016
Period: Thursday, December 31, 2015
Industry: Pharmaceutical Preparations

External Resources:

Bookmark the Permalink:
https://last10k.com/sec-filings/737207/0001571049-16-013489.htm